RxDoctor Payments Data

Sara Morrison, APRN

Family · Marysville, OHNPI 1346940749

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 94 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$460
  • AbbVie$393
  • Novo Nordisk$146
  • Pfizer$95
  • Amgen$87
  • Mylan Specialty L.p.$41
  • plus $436 from 16 others

What the payments were for

  • Food & beverage$1,64499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,658 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$29,104
Medicare patients
182
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$45,107
EliquisApixaban31$28,010
MounjaroTirzepatide18$26,915
JardianceEmpagliflozin27$20,097
RybelsusSemaglutide12$19,488
OzempicSemaglutide19$19,081
FarxigaDapagliflozin Propanediol12$15,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,132
XareltoRivaroxaban13$11,243
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$3,761
PremarinEstrogens, Conjugated12$3,201
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,285
Gabapentin144$1,581
Esomeprazole Magnesium17$1,494
Albuterol Sulfate HfaAlbuterol Sulfate54$1,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$45,10711 claims
Novo NordiskRybelsus, Ozempic$146$38,56831 claims
PfizerEliquis, Premarin$95$31,21143 claims
Lilly USA, LLCMounjaro$460$26,91518 claims
Boehringer IngelheimJardiance$32$20,09727 claims
AstraZenecaFarxiga$29$15,73312 claims
GSKTrelegy Ellipta$34$12,13213 claims
AbbVieSynthroid$393$96019 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$71490 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Marysville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →